Real-World Observational Study on Patient-Reported Outcomes in the Treatment of Insomnia With Daridorexant in Canada

Conditions

• Insomnia

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Daridorexant 50 mg — DRUG
  As indicated by the physician

Study Details

The purpose of this observational study is to evaluate the impact of daridorexant on quality of life, work productivity and insomnia symptoms in Canadian adults suffering from insomnia.

Key Dates

First listed

Mar 15, 2024

Start date

Jun 20, 2024

Status verified

May 2026

Primary completion

May 19, 2026

Completion

May 19, 2026

Study Design

Enrollment

90 participants (actual)

Arms

• Arm: daridorexant
  Patients who have been newly prescribed oral tablets of daridorexant 50 mg to treat their insomnia

Primary Outcome Measure

Change from Baseline in Quality of Life [ Time Frame: Month 1, Month 2, Month 3 ]

Find similar trials

Related Studies

• Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
  Recruiting · Duke University · Palo Alto, California
• NiteCAPP: Web-based Interventions for Insomnia in Rural Dementia Caregivers
  Recruiting · University of South Florida · Tampa, Florida
• Treatments for Insomnia in Veterans With PTSD
  Recruiting · VA Office of Research and Development · Sepulveda, California
• Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior
  Recruiting · Jeff Bridge · Columbus, Ohio